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This work was conducted to prepare β-caryophyllene-hydroxypropyl-β-cyclodextrin
inclusion complex (HPβCD/BCP) and investigate its effects andmechanisms on cognitive
deficits in vascular dementia (VD) rats. First, HPβCD/BCP was prepared, optimized,
characterized, and evaluated. HPβCD/BCP and AM630 were then administered to VD
rats to upregulate and downregulate the cannabinoid receptor type 2 (CB2). Results
showed that HPβCD/BCP can significantly increase the bioavailability of BCP. Through
the Morris water maze test, HPβCD/BCP can attenuate learning and memory deficits
in rats. Cerebral blood flow (CBF) monitoring results indicated that HPβCD/BCP can
promote the recovery of CBF. Moreover, molecular biology experiments showed that
HPβCD/BCP can increase the expression levels of CB2 in brain tissues, particularly the
hippocampus and white matter tissues, as well as the expression levels of PI3K and
Akt. Overall, the findings demonstrated the protective effects of HPβCD/BCP against
cognitive deficits induced by chronic cerebral ischemia and suggested the potential of
HPβCD/BCP in the therapy of vascular dementia in the future.
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INTRODUCTION
Chronic cerebral hypoperfusion cases are widely distributed in elderly people (Xi et al., 2014).
Considerable studies showed that a reduction in cerebral blood flow (CBF) might affect learning
and memory processes, resulting in the development, and progression of dementia, such as
vascular dementia (VD) (Farkas et al., 2007; Liu and Zhang, 2012). VD is a chronic syndrome
caused by ischemic cerebrovascular diseases (Enciu et al., 2011), and is believed to be the
second most common type of dementia (Gunstad et al., 2005). VD is often characterized by a
progressive cognitive and behavioral deterioration, which is induced by blood loss in brain areas
like hippocampus and white matter (Kalaria et al., 2004). To date, no specific drug can cure VD.
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Thus, an increasing number of studies have focused on the
development of effective drugs to treat VD.
β-caryophyllene (BCP) is a natural sesquiterpene compound
found in the essential oil of plants and has been reported to be
a cannabinoid receptor type 2 (CB2) selective agonist (Gertsch
et al., 2008; Al Mansouri et al., 2014). BCP can effectively prevent
Alzheimer’s disease (AD) (Cheng et al., 2014). Some studies
revealed that BCP exerts a prominent protective effect on cerebral
neurons (Assis et al., 2014) and thus might be beneficial in the
prevention and treatment of cerebral diseases (Guo et al., 2014).
BCP can also generate neuroprotective effects in ischemic models
(Choi et al., 2013). However, little is known about the role of BCP
in VD. Therefore, we examined the effects and mechanisms of
BCP on VD rats.
The bilateral common carotid artery clamping (two-vessel
occlusion, 2VO) was used to achieve chronic cerebral ischemia
(Farkas et al., 2007). The CBF changed substantially after 2VO,
thus, the CBF values can be used to evaluate the degree of
ischemia and investigate the drug effects. Morris water maze
(MWM) is acknowledged as a validated test for the evaluation of
the spatial learning andmemory retention abilities of rats (Morris
et al., 1982; D’Hooge and De Deyn, 2001).
In previous studies, BCP exhibited poor water solubility
and volatile sensitivity to light, oxygen, humidity, and high
temperatures (Sköld et al., 2006). These conditions decrease the
bioavailability and limit the pharmacologic action of the drug.
Thus, our present study was conducted to develop a delivery
system for BCP to improve its solubility and bioavailability.
In particular, hydroxypropyl-β-cyclodextrin (HPβCD) was used
in this study. β-Cyclodextrins (β-CDs) are widely used as
complexing agents to enhance the stability, aqueous solubility,
dissolution rate, and bioavailability of drug molecules (Mennini
et al., 2014; Aiassa et al., 2015). HPβCD, a derivative of β-CD,
is proven to be a safe vehicle that increases drug solubility
and bioavailability (Brewster and Loftsson, 2007; Garnero et al.,
2010). Various injectable products containing HPβCD are
approved by the FDA for commercial use, such as Mitomycin
fromMitoExtra and Itraconazole from Sporanox (Maragos et al.,
2009).
In the present study, an injectable β-caryophyllene
/hydroxypropyl-β-cyclodextrin inclusion complex
(HPβCD/BCP) was prepared for VD treatment, and its
contributions on the alleviation of cognitive impairment in
VD rats were investigated. First, HPβCD/BCP was prepared,
characterized and administered to rats with chronic cerebral
ischemia. MWM test, CBF monitoring, brain histology, and
biochemical analyses were then performed to evaluate the effects
of BCP on rat brains after 2VO. The results may provide an
innovative approach with potential clinical benefits of BCP for
VD.
MATERIALS AND METHODS
Materials
BCP was purchased from Adamas Reagent Co., Ltd (Basel,
Switzerland). AM630 was purchased from Cayman Chemical
Company (Michigan, USA). Naphthaline (internal standard,
purity ≥99.0%) was purchased from Xiya Reagent (Chengdu,
China). HPβCDwas purchased from Shandong Binzhou Zhiyuan
Biotechnology Co., Ltd. (Shandong, China). Olive oil was
purchased from Xiya Reagent (Chengdu, China).
Preparation and Characterization of
HPβCD/BCP
Preparation of HPβCD/BCP and Determination of
Inclusion Efficiency
The HPβCD/BCP was prepared through solution-stirring and
freeze-drying method (Xu et al., 2014). HPβCD was weighed
and placed in a vial with 10 mL water and magnetic stirring
bar and then placed in a constant temperature magnetic stirring
apparatus. After stirring for 1 h, the BCP dissolved in ethanol
was added into the saturated HPβCD solution. The mixture was
stirred continuously and then cooled down to room temperature
(25◦C). The cooled mixture was then filtered with a millipore
filter (0.45µm). The filtrate was frozen at−20◦C for 5 h and then
at−80◦C overnight. Afterward, the samples were freeze-dried in
a vacuum freeze dryer (Beijing Boyikang Laboratory Instruments
Co., Ltd, Beijing, China) for 24 h. The HPβCD/BCP was obtained
thereafter.
The inclusion efficiency of HPβCD/BCP was determined by a
gas chromatography (GC) (Liu et al., 2013). A gas chromatograph
(GC2014C, SHIMADU, Japan) with a flame ionization detector
and a Wonda Cap 5 (30m × 0.25 nm × 0.25 µm) capillary
column was used. The HPβCD/BCP lyophilized powder was
dissolved in 1.001 mg/mL naphthaline-ethanol solution and then
detected by the GC. The vaporizing chamber temperature was
set at 250◦C. The oven temperature was initially set at 100◦C,
programmed to 140◦C at 15◦C/min, held for 0.5 min, followed
by 30◦C/min to 270◦C and then finally held for 5 min. Hydrogen
was used as carrier gas at a flow rate of 1.62 mL/min. The sample
volume was 1 µL, and the inlet had a split ratio of 20:1. The
inclusion efficiency % was calculated as follows:
Inclusion efficiency (%) = (mass of BCP in
HPβCD/BCP)/(mass of added BCP).
Optimization of the Prescription
A central composite design (Lou et al., 2014) was used to
elucidate the main effects and interactions of the parameters,
such as material inputting ratio (X1), reaction temperature (X2),
and reaction time (X3). The inclusion efficiency was assigned as
the indicator for the selection of the optimum formulation. A
three-factor and five-level factorial design was employed for the
optimization procedure with different material inputting ratios,
reaction temperature, and time as prime selected independent
variables. The values of the five coded levels of the three factors
were then assumed after preliminary trials. The values are
presented inTable 1. The inclusion efficiency of each formulation
was measured as response values. Design-Expert software (8.05b)
was used to generate and evaluate of the statistical experimental
design.
Characterization of HPβCD/BCP Inclusion Complex
The HPβCD/BCP was characterized by ultraviolet
spectrophotometry (UV), differential scanning calorimetry
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TABLE 1 | Experimental design of independent parameters in the
Box-Behnken design.
Independent parameters Symbol Range and level
−1.682 −1 0 1 1.682
Material inputting ratio (n/n) X1 0.2 0.36 0.6 0.84 1
Reaction temperature (◦C) X2 30 38 50 62 70
Reaction time (h) X3 1 1.8 3 4.2 5
(DSC) and Fourier transform infrared spectroscopy (FT-IR).
The formation of HPβCD/BCP was determined using a UV–vis
spectrophotometer (UV-2600, SHIMADZU, Japan). HPβCD (21
mg) and BCP (10µL) were dispersed separately in 10mL distilled
water to obtain the HPβCD and BCP solutions, respectively.
HPβCD/BCP lyophilized powder (22 mg) was added to 10 mL
distilled water to obtain the HPβCD/BCP solution. HPβCD
(20 mg) and BCP (10 µL) were added into a mortar, and then
ground homogeneously. The ground powder was dissolved in 10
mL distilled water to obtain a physical mixture solution. All the
samples above were centrifugated to obtain their supernatants.
The supernatants were scanned in the range of 200–800 nm to
obtain the UV–vis absorption spectrum.
DSC analysis of HPβCD, BCP, their physical mixture and
HPβCD/BCP were performed using STA 449C thermal analyzer
(Netzsch Corporation, Germany). Samples were weighed
accurately and sealed in aluminum pans. They were then placed
in the instrument and heated at a rate of 15◦C/min from 40 to
350◦C under a constant flow (25 mL/min) of nitrogen gas. An
empty sealed pan was used as a reference (Tang et al., 2015).
Subsequently, HPβCD, BCP, the physical mixture and
HPβCD/BCP were characterized using iS50 FT-IR (Nicolet,
Thermo Scientific, USA). The FT-IR spectrum of each sample was
collected from 4000 to 400 cm−1. HPβCD, the physical mixture
and HPβCD/BCP were ground and mixed with spectrograde
KBr powder at a mass ratio of 1:100. The resulting mixture was
pressed forcibly into round disks with 8 mm diameter. BCP
was dropped and spread on a KBr disk uniformly. The FT-IR
spectra of all the samples were analyzed using the OMNIC 9.2
spectrophotometer software.
In vitro Dissolution Study
In vitro dissolution studies of HPβCD/BCP were performed
according to Pharmacopoeia of the People’s Republic of
China (2010 Edition, Part 2, Appendix XC. No.1 method;
National Pharmacopoeia Committee, 2010) by using a ZRS-6G
Dissolution Apparatus (Tiandatianfa Science and Technology
Co., Ltd, Tianjin, China). Phosphate buffer solution (PBS, pH
6.8) was used as release medium. To demonstrate the dissolution
of the inclusion complex, the BCP–HPβCD physical mixture
were used as contrast. The HPβCD/BCP lyophilized powder
and the physical mixture were added into the rotating baskets
and installed onto the dissolution apparatus. Subsequently, the
baskets were placed into the PBS and stirred at 50 rpm at 37 ±
0.5◦C. Approximately 5 mL of the release medium was drawn at
appropriate intervals (5, 10, 20, 30, 45, 60, 90, 120, 180, 300 min),
and replaced with 5ml freshmedium simultaneously. All samples
were centrifuged at 12,000 rpm for 5 min and then submitted
to UV analysis at 205 nm upon proper dilution. The release
profile of the formulation was expressed as cumulative release
percentage vs. time.
In vivo Experiments Protocol and Pharmacokinetic
Analysis
In vivo experiments were performed on SD rats. Rats were
provided by the Laboratory Animal Center, Chongqing Medical
University, China. The rats were housed in cages with constant
temperature (22◦C) and humidity (55%) and under a 12 h light–
12 h dark cycle (lights on 06.00–18.00 h). The rats had free
access to food and water. The experiment protocol was approved
by the Animal Experimental Committee, Chongqing Medical
University. Rats were randomly divided into two groups with
five rats each. The first group (HPβCD/BCP group) received
HPβCD/BCP by intraperitoneal injection. The second group
(BCP-olive group) received BCP-olive solution by intraperitoneal
injection. Up to 0.5 mL blood samples were collected from
the orbit venous plexus of each rat and transferred separately
into heparinized eppendorf tubes at predetermined time points
(0.167, 0.333, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 h) after drug
administration.
Blood samples were centrifuged at 12,000 rpm for 5 min to
separate the plasma. The plasma samples were stored in the
refrigerator at −20◦C. Before analysis, 100 µL plasma, 90 µL
ethyl acetate, and 10 µL internal standard naphthaline (5.035
µg/mL) were added into a centrifuge tube and vortexed for
5 min. Each sample was then centrifuged at 3200 rpm for
10 min and the supernatant (60 µL) was collected for GC
analysis. The pharmacokinetic parameters of BCP-olive and
HPβCD/BCP in SD rats were calculated using a DAS2.0 practical
pharmacokinetics program. A non-compartment model was
used to analyze the in vivo distribution of the drug.
Surgery
The VD rat model was established by 2VO for 4 weeks. The
rats were weighed and then anesthetized with chloral hydrate
(3.5 mL/kg, i.p.). After disinfection, a midline neck incision
was performed and bilateral common carotid arteries of rats
were exposed and ligated with 4-0 type surgical silk to induce
cerebral ischemia. The sham-operated rats were operated using
the same procedures except ligation. During the surgery rats were
maintained at 37.0± 0.5◦C.
Drug Administration and Experimental
Protocol
A total of 84 adult male SD rats weighing 300–350 g were
randomly divided into sham-operated group (sham group), 2VO
group, HPβCD/BCP treated groups and AM630 treated group
(3 mg/kg). The sham and 2VO groups were treated with normal
saline containing HPβCD. The HPβCD/BCP treated groups were
further subdivided into three groups, namely, high-, middle-
, and low-dose groups treated with 144, 48, and 16 mg/kg
BCP, respectively. AM630 was dissolved in dimethyl sulfoxide
(DMSO) and then administered to the rats (3 mg/kg). At 4
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weeks after 2VO surgery, all the groups were intraperitoneally
injected with the corresponding solution once a day for 4 weeks.
The MWM task was processed 50 days after 2VO. The overall
experimental protocol is shown in Figure 1.
Morris Water Maze Task
The MWM task was conducted in all rats 22 days after drug
administration to evaluate their spatial learning and memory
retention. The MWM (ZS-001, ZSDichuang) consisted of a
circular swimming tank with a diameter of 150 cm and depth of
60 cm. The tank was divided into four quadrants with different
markers. A camera was installed above the tank to record the
behavior of the rats. A 15 cm-wide circular platformwas placed in
the tank and submerged by opaque black water. Each testing rat
was thrown into the water at one of the four quadrants and was
given 120 s to find the platform. The rats that failed to locate the
platform were guided to the platform and retained for 20 s. The
rats were administered with the corresponding formulations after
MWM test once a day during the protocol. The MWM task was
conducted in two stages. The first stage was the navigation test.
On the first day, the platform was visible to the rats and the time
of reaching the platform was recorded. In the subsequent days,
the rats were tested twice a day, and the platformwas hidden. The
tests were continuously repeated 4 days to examine the indicators
of escape latency, swimming track, times of crossing the platform,
time of staying at the aim quadrant and path length at the aim
quadrant. The second stage of spatial probe test was performed
on the sixth day, and the platform was removed. The values of
each indicator were recorded and analyzed to assess the learning
and memory performances of the rats. The evaluator conducting
the MWM tests was blinded to the experiment protocol.
Cerebral Blood Flow Monitoring
CBF was monitored using a laser doppler perfusion and
temperature monitor (Moor VMS-LDF1, Moor Instruments,
UK). The rats of each group were anesthetized with chloral
hydrate (3.5 mL/kg, i.p.). A paramedian skin incision was
performed, and the subcutaneous tissue and cranial fascia were
dissected to reach the skull bone. The probe of the monitor was
placed at the settled skull bone area to detect the CBF (Cuccione
et al., 2016). CBF changes in the rats were monitored before 2VO
operation at the following successive periods: 1, 6, 24 h, 3, 7, 14,
and 28 days after operation, as well as 1, 7, 14, and 28 days after
drug treatment.
Immunohistochemistry
The expression of the CB2 was determined by
immunohistochemical staining in the brain as described in
our previous study (Teng et al., 2016). The rats were anesthetized
and then transcardially perfused with 0.9% sodium chloride and
fixed with 4% paraformaldehyde. The brains were segregated
and embedded in paraffin and subsequently sectioned. The
sections were deparaffinized in xylene and rehydrated in ethanol
solutions. The antigen was retrieved in boiled water bath using
a 0.01 M citrate solution (pH 6.0) for 15 min. The sections
were cooled down to room temperature and washed in PBS for
10 min before incubation in a goat serum blocking solution
for 40 min. The sections were then incubated with primary
antibodies directed against the CB2 [CB2 (H-60), diluted in 1:25,
Santa Cruz, USA] overnight at 4◦C. After washing with PBS,
the sections were incubated with biotinylated goat anti-rabbit
antibodies (1:200, Zhongshan Golden Bridge Biotechnology,
ZSGB-Bio, China) for 30 min at 37◦C The sections were
counterstained with 3, 3-diaminobenzidine (DAB, ZSGB-Bio,
China) and then incubated in PBS for use as negative controls.
The immunohistochemically stained tissue sections were
observed under a microscope. This procedure was performed
by an author blinded to the experimental protocol. The number
of positively immunostained cells in the CA1 region of the
hippocampus was counted randomly in five microscopic fields
at 400× magnifications. The positive rate in the nerve fibers
was eveluated using ImagePro plus software and represented as
integrated optical density (IOD).
Western Blot Analysis
Frozen hippocampus samples were mechanically homogenized
in RIPA lysis buffer (Beyotime, China), and then centrifuged
at 12,000 rpm for 15 min at 4◦C. Protein concentration was
determined using a BCA Protein Assay Kit (Beyotime). Proteins
mixed with loading buffer were separated via 10% SDS-PAGE
(Beyotime) and electrically transferred onto a polyvinylidene
fluoride (PVDF) membrane (Millipore, USA; Lou et al., 2016).
This membrane was then blocked with 5% bovine serum
albumin (BSA) for 1 h at room temperature. The blocked
membrane was incubated overnight at 4◦C with primary
antibodies directed against CB2 (Santa Cruz), phospho-Akt
(p-Akt) (Cell Signaling, USA), Akt (Santa Cruz) and PI3K
(Proteintech, China) diluted in Western blot primary antibody
diluents at 1:200, 1:1000, 1:500, and 1:1000 respectively. After
FIGURE 1 | Schematic demonstrates overall experimental process.
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being washed thrice with PBS+Tween 20 (PBST), themembrane
was incubated with horseradish peroxidase (HRP)-conjugated
secondary antibody (diluted 1:3000 in PBST; Beyotime) for 1 h
at 37◦C. The immunoreactivity of the membrane was detected by
chemiluminescence (ECL, Beyotime, China). Band densitometric
analysis was performed using the ChemiDoc detection system
and Quantity One software (Bio-Rad).
TUNEL Staining
A TUNEL staining was performed on the paraffin-embedded
sections to assess neuronal apoptosis in the brain tissues. The
sections were processed using an in situ cell death detection
kit (Roche, Switzerland; Teng et al., 2016). The sections were
dewaxed in xylene, ethyl alcohol, distilled water, and PBS and
then incubated with Proteinase K, 0.1% sodium citrate andH2O2.
After the slides were washed with PBS, they were incubated
with 20 µL TUNEL reaction mixture at 37◦C for 60 min.
The sections were washed and incubated with 20 µL POD at
37◦C for 60 min. TUNEL-positive cells were identified, counted,
and analyzed under a light microscope (Leica, Germany) by a
researcher who was blinded to the experimental groups. The
level of brain damage was evaluated using the apoptotic index,
which was the average number of positive cells counted in five
microscopic fields at 400×magnifications in each CA1 region of
the hippocampus section.
HE Staining
After the MWM tests, rats were anesthetized and perfused
through the left cardiac ventricle with PBS and then 4%
paraformaldehyde. The brains were removed and fixed. The fixed
tissues were embedded in paraffin. The brains were serially sliced
to 5 µm-thick sections. The sections for hematoxylin-eosin (HE)
staining were placed onto the uncoated slides. The sections were
thenHE stained routinely for histomorphological assessment (Xu
et al., 2012). The evaluator assessing the histology was blinded to
the experiment protocol.
Statistical Analysis
All experimental results were presented as mean ± standard
deviation (SD). All the experimental data were statistically
analyzed by SPSS 17.0. The group differences in the tests were
analyzed by one-way analysis of variance (ANOVA) or Student’s
t-test. The P < 0.05 was considered statistically significant.
RESULTS
Preparation and Evaluation of HPβCD/BCP
Preparation and Optimization of HPβCD/BCP
The inclusion efficiency of different prescriptions ranged from
12.3 to 56.9% and was determined from the 20 experimental runs
generated by the central composite design. The effects of the three
independent variables (X1, X2, and X3) on the inclusion complex
were examined by analyzing the inclusion efficiency values.
Figure 2 shows the effects of X1, X2, and X3 on the inclusion
efficiency. The results indicated that the inclusion efficiency
increased when X1 and X3 decreased while X2 increased.
Considering the stability of BCP, we determined that the
optimized formulation achieved a material inputting ratio of
BCP and HPβCD at 0.2, reaction temperature of 50◦C and
reaction time of 3 h. The optimized inclusion complex showed
an inclusion efficiency of 56.9%.
Validation of HPβCD/BCP
UV–vis spectrophotometry, DSC, and FT-IR were used to
validate the formation of HPβCD/BCP. UV–vis absorption
spectra were acquired and recorded for HPβCD, BCP, the
physical mixture, and the HPβCD/BCP. No absorption peak is
observed in Figure 3A. The UV–vis spectra of BCP (Figure 3B)
and the physical mixture (Figure 3C) were identical, and
both achieved a maximum absorption wavelength of 205 nm.
However, no absorption peak was found in the spectrum of the
HPβCD/BCP (Figure 3D). The results indicated that BCP had
been wrapped into the HPβCD, forming an inclusion complex
with the latter.
DSC is an important technique that can verify the formation
of inclusion complex. The melting, boiling, and sublimation
points of the drug molecules either shift to different temperatures
or disappear when these molecules are inserted in the HPβCD
cavities. The thermograms of HPβCD, BCP, the physical mixture,
and the HPβCD/BCP are shown in Figure 4. The absence of
the peak of BCP in the thermogram of HPβCD/BCP may be
attributed to the inclusion of BCP into the HPβCD cavity,
suggesting the formation of the HPβCD/BCP.
The HPβCD/BCP was characterized by FT-IR spectroscopy.
The spectra of HPβCD, BCP, HPβCD/BCP, and their physical
mixture from 4000 to 400 cm−1 are presented in Figure 5.
The BCP spectrum showed the bands at 3070–2680 and 1637–
870 cm−1 (Figure 5A). The spectrum of the physical mixture
(Figure 5B) presented a weak characteristic absorption band of
BCP at 885 cm−1. The spectrum of HPβCD (Figure 5C) showed
a remarkable absorption bands at 3401 cm−1 (Tang et al., 2015).
However, compared with the spectrum of the HPβCD/BCP few
features were observed to be identical to BCP (Figure 5D). The
main differences can be ascribed to the formation of the inclusion
complex related to the intramolecular hydrogen bonds between
BCP and HPβCDmolecules.
Evaluation of HPβCD/BCP
The HPβCD/BCP was evaluated both in vitro and in vivo.
Figure 6 shows the dissolution profiles of the HPβCD/BCP and
their physical mixture in PBS (pH 6.8). They were characterized
by an initial fast release followed by a relatively slow release until
a constant value.
The results of pharmacokinetic study of BCP-OLIVE and
HPβCD/BCP are shown in Figure 7. The plasma content of
BCP administered with HPβCD/BCP was significantly higher
at all time points in comparison to that obtained after injection
of BCP-OLIVE. The relevant pharmacokinetic parameters of
BCP in rat plasma after injection with the two formulations
were calculated. The parameters are summarized in Table 2.
The results demonstrated that HPβCD/BCP prominently
increases the bioavailability of BCP in rats as compared with
BCP-OLIVE.
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FIGURE 2 | Response surface plots showing effects of material inputting ratio (X1), reaction temperature (X2), and reaction time (X3) on inclusion
efficiency. The inclusion efficiency of inclusion complex increased when X1 and X3 decreased while X2 increased. (A) Effects of X1 and X2 on inclusion efficiency. (B)
Effects of X2 and X3 on inclusion efficiency. (C) Effects of X1 and X3 on inclusion efficiency.
FIGURE 3 | UV–vis absorption spectra of (A) HPβCD, (B) BCP, (C) physical mixture, and (D) HPβCD/BCP. No absorption peak is observed in HPβCD. The spectra
of BCP and the physical mixture were identical, and both achieved a maximum absorption wavelength of 205 nm. No absorption peak was found in the spectrum of
the HPβCD/BCP.
Frontiers in Pharmacology | www.frontiersin.org 6 January 2017 | Volume 8 | Article 2
Lou et al. HPβCD/BCP Improves Vascular Dementia
FIGURE 4 | DSC curves of (A) BCP, (B) HPβCD, (C) physical mixture, and (D) HPβCD/BCP. BCP generated a wide exothermic peak from 180 to 260◦C. HPβCD
exhibited an endothermic peak at 60◦C. An exothermic peak of physical mixture appeared at 190◦C. An endothermic peak of HPβCD/BCP appeared at 70◦C, but no
peak showed up from 180 to 260◦C.
FIGURE 5 | FT-IR spectra of (A) BCP, (B) physical mixture, (C) HPβCD, and (D) HPβCD/BCP. The BCP spectrum showed the bands from 3070 to 2680 cm−1 and
1637 to 870 cm−1. The physical mixture presented the absorption band of BCP at 885 cm−1. HPβCD showed a absorption bands at 3401 cm−1. HPβCD/BCP
showed only a few identical features compared with BCP.
FIGURE 6 | Mean dissolution profiles of HPβCD/BCP and their physical mixture in the mediums phosphate buffer (pH 6.8) (n = 3).
Frontiers in Pharmacology | www.frontiersin.org 7 January 2017 | Volume 8 | Article 2
Lou et al. HPβCD/BCP Improves Vascular Dementia
FIGURE 7 | Mean (±S.D.) plasma concentration–time profiles of BCP-OLIVE and HPβCD/BCP by intraperitoneal injection at a dose of 50 mg/kg (n = 5).
The plasma content of BCP administered with HPβCD/BCP was higher at all time points in comparison to that obtained after administered with BCP-OLIVE.
TABLE 2 | Pharmacokinetic parameters of different formulations.
Pharmacokinetic parameters BCP-OLIVE HPβCD/BCP
Cmax (µg/ml) 1.7578 ± 0.2069 2.7796 ± 0.3445
Tmax (h) 1.7000 ± 0.1225 1.6000 ± 0.1871
T1/2(h) 2.0046 ± 0.4276 2.6168 ± 0.3858
MRT (h) 3.0996 ± 0.2942 3.8094 ± 0.2696
AUC 0−12h (µg*h/ml) 5.0086 ± 0.8860 9.0264 ± 1.6495
AUC0-∞(µg*h/ml) 5.4722 ± 0.0815 9.6428 ± 1.5587
Protective Effects of HPβCD/BCP in 2VO
Model
The effects of BCP on the spatial learning and memory of rats
were examined through the MWM test. All the rats without
training reached the platform in the visible platform task on
the first day (Figure 8A). In the MWM training, the rats in
the 2VO group and AM630 group performed longer escape
latencies than the rats in the sham group and HPβCD/BCP
treated group (Figure 8B). The abilities of spatial learning and
memory retention of rats were evaluated using the times of
crossing platform, time of staying at the aim quadrant and path
length at aim quadrant in the spatial probe tests performed on
the sixth day. Compared with rats in the sham group, rats in
the 2VO group exhibited less times of crossing platform, time
of staying at the aim quadrant and path length at aim quadrant
(P < 0.05 all). The spatial learning and memory of rats in the
HPβCD/BCP treated group improved significantly compared
with rats in the 2VO group, especially in themiddle and high dose
groups (P < 0.05 in middle-dose and P < 0.001 in high-dose vs.
2VO group). The times of crossing the platform and path length
at aim quadrant of rats in the AM630 group were apparently
lower than those of the 2VO group (P < 0.05, Figures 8C,E).
Although the test of time of staying at aim quadrant showed
no significant difference between the two groups (P > 0.05), a
decreasing trend was observed in the AM630 group (Figure 8D).
The CBF values of the rats before 2VO operation, after
operation and after drug treatment were monitored to detect
the effects of HPβCD/BCP on CBF (Figure 9). All tests results
were expressed as CBF recoveries, which were calculated as the
percentage of the residual perfusion after 2VO compared with
pre-operation baseline. CBF of all rats declined distinctly after
2VO except that in the sham group. After the operation, the CBF
recovered relatively slowly. The recoveries of the different groups
were approximate before drug treatment and slowly rebounded
to about 36.1–39.7% at 28 days after operation. After the drug
treatment, the recoveries continued to rise rapidly. At the 28th
day after drug treatment, the CBF of rats in 2VO was still lower
than that of the sham-operated rats (P < 0.001), but the CBFs of
rats in the high dose HPβCD/BCP treated group recovered faster
than those in the 2VO group (P < 0.05). The CBF recovery in
low- and middle-dose HPβCD/BCP treated group did not show
significant statistical differences with those in the 2VO group
(P > 0.05). However, a faster recovery rate was observed in
the HPβCD/BCP treated groups. The CBF in the AM630 group
presented the slowest recovery among all the groups.
HE staining was used to detect the effects of HPβCD/BCP on
the morphological changes in the hippocampal neurons of the
CA1 region. In the sham group, morphology of the hippocampal
neurons was inerratic, the nuclei were mellow and full, stained
in blue, endochylema was completely filled and stained in
pink (Figure 10A). Figure 10B shows the hippocampus in the
rats in the 2VO group. In these hippocampus, some neurons
exhibited paramorphia and were stained in blue, and their nuclei
became triquetrous or polygonous with irregular morphology.
The cytoplasms of the variant neurons were stained in dark
red or dark violet, and the nerve fibers were fractured and
reduced. In the hippocampus of the HPβCD/BCP treated rats,
the number of abnormal neurons was less than that in the 2VO
Frontiers in Pharmacology | www.frontiersin.org 8 January 2017 | Volume 8 | Article 2
Lou et al. HPβCD/BCP Improves Vascular Dementia
FIGURE 8 | MWM test results of rats’ performance. (A) Visible platform task on the first day. (B) Mean escape latency calculated for each day in sham, 2VO, BCP
treated low-dose, middle dose, high dose and AM630 treated group in navigation test. Results of (C) times of crossing platform, (D) time of aim quadrant, (E) path
length of each group in spatial probe tests. All the rats reached the platform in the visible platform task on the first day. The rats in the 2VO group and AM630 group
performed longer escape latencies than other groups in the MWM training. Compared with rats in the sham group and BCP treated groups, rats in the 2VO group and
AM630 group exhibited less times of crossing platform, time of staying at the aim quadrant and path length at aim quadrant. (*P < 0.05 vs. sham group, #P < 0.05
vs. 2VO group, ##P < 0.001 vs. 2VO group).
rats. In addition, the nuclei and cytoplasm of their neurons were
polygonous, their colors, and morphologies slightly changed
(Figures 10C–E). In the hippocampus of the AM630 treated rats
(Figure 10F), the neurons were distinctly abnormal, and most of
them were triquetrous and wedge-shaped, some neurons were
fusiformis in shape. The nuclei were highly irregular and darkly
stained. The cytoplasm was aggregated and stained in dark violet.
The nerve fibers in the AM630 group were obviously fractured
and reduced.
The effects of HPβCD/BCP on the apoptosis of the
hippocampal neurons caused by 2VO are presented in Figure 11.
The TUNEL positive cells were darkly stained and regarded as
apoptotic cells. Compared with the sham group, the TUNEL
positive cells in the 2VO group significantly increased in the
CA1 region of hippocampus (P < 0.01, Figure 11B). After
HPβCD/BCP treatment, the number of darkly stained cells
was obviously suppressed relative to that in the 2VO group,
which was exerted in a dose-dependent manner (P < 0.05 in
low- and middle-dose groups, and P < 0.001 in high-dose
group, Figures 11C–E). The CB2 inhibitor, AM630, can further
aggravate apoptosis in the hippocampus compared with the 2VO
rats, although no statistical difference was observed (P = 0.71,
Figure 11F).
Effect of HPβCD/BCP on the CB2 Pathway
after 2VO
The expression levels of the CB2 were detected by
immunohistochemical staining (Figure 12). In the brain
tissues of sham-operated rats, the CB2 were mainly expressed in
the cytoplasm of the neurons and nerve fibers (Figure 12A). In
the 2VO group (Figure 12B), the expression levels of the CB2
significantly increased in the corona radiata (a), pyramidal tract
(b) and hippocampus (c). The HPβCD/BCP group significantly
increased the CB2 after 2VO operation compared with the 2VO
group, and the CB2 expression levels increased with the increase
of BCP concentration (Figures 12C–E). However, in the AM630
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FIGURE 9 | CBF monitoring results of each group. The CBF recoveries of
the different groups were approximate before drug treatment, while the
recoveries rised rapidly after the drug treatment. At the 28th day after drug
treatment, the CBFs of rats in the high dose HPβCD/BCP treated group
recovered faster than those in the 2VO group, and the AM630 group presented
the slowest recovery. (*P < 0.001 vs. sham group, #P < 0.05 vs. 2VO group).
group, the CB2 presented extremely low expression levels in
the brain tissue, which verified the suppression effect of AM630
(Figure 12F).
The expression levels of the CB2, PI3K, Akt, and p-Akt were
detected by Western blot (Figure 13). Although the expression
levels of the CB2, as well as PI3K, increased slightly in the 2VO
group compared with those in the sham group, the expression
levels in these groups showed no statistical difference. After
HPβCD/BCP treatment, the CB2 expressed incrementally with
the incremental dose of BCP (P < 0.05 in low- and middle-dose
groups vs. 2VO group, P < 0.01 in high-dose group vs. 2VO
group). AM630 inhibited the expression of the CB2 as indicated
by the reduced CB2 expression in the 2VO group (P < 0.05), and
this finding corresponded to the immunohistochemical staining
result. The expression levels of PI3K and p-Akt were similar
to that of CB2. Compared with those of the 2VO group, the
expression levels of the P13K, p-Akt, and CB2 increased in the
HPβCD/BCP treated groups, especially in the high-dose group
(P < 0.05 in PI3K, and P < 0.01 in p-Akt), whereas these levels
decreased in the AM630 treated group (P < 0.05). These results
indicated that the activation of the CB2 regulated the expression
levels of PI3K and p-Akt.
DISCUSSION
In this study, we successfully developed the HPβCD/BCP, which
will be used for subsequent research. The inclusion complex was
prepared by solution-stirring and freeze-drying method and then
evaluated by UV–vis spectrophotometry, DSC, FT-IR, in vitro
dissolution study and in vivo pharmacokinetic study. The MWM
test and CBF monitoring confirmed the establishment of VD
model by 2VO. In addition, the HPβCD/BCP can improve the
learning and memory abilities in rats and promote the recovery
of CBF.Molecular biology experiments proved that HPβCD/BCP
can alleviate the injury of neurons and nerve fibers, and its effect
may be promoted by upregulating the CB2-PI3K-Akt pathway.
VD induced by chronic cerebral ischemia is often
characterized by a progressive cognitive deterioration induced
by blood reduction in vulnerable brain regions. Previous studies
found that a decrease in CBF can damage the neurons in the
vulnerable regions of the brain, especially in the hippocampus
and white matter (Kitamura et al., 2016). Damage in the
hippocampus neurons and loss of white matter fibers can disrupt
the learning ability and cause memory, which in turn can result
in dementia. Damage to the hippocampus can cause memory
loss (Clark et al., 2007). Given that spatial learning and memory
were dependent on the integrity of the hippocampus (Xu et al.,
2012), deficits in spatial learning and memory were found
in the presence of lesions in the hippocampus (Clark et al.,
2007). Moreover, cerebral white matter is extremely vulnerable
to ischemia. Damage to white matter is mainly manifested as
injury to oligodendrocytes and distruction of myelinated axons
(Kitamura et al., 2012). Lesions in white matter can disrupt
nerve conduction, and this effect may result in dementia. In
our study, the rats that underwent 2VO operation exhibited
declined learning and memory abilities in the MWM test, as
well as low CBF level. HE and TUNEL staining indicated that
VD rats exhibited increased neurons paramorphia, apoptosis,
degeneration, and loss of nerve fibers.
BCP generates neuroprotective effects against ischemic
diseases and AD models (Choi et al., 2013; Cheng et al., 2014)
through its anti-inflammation, anti-apoptosis, antioxidation
effects, as well as the activation of CB2. However, studies on
the effects of BCP on VD are few. Despite the effectiveness
of BCP in neuroprotection, its properties such as poor water-
solubility, volatility, and sensitivity, decrease the bioavailability
and limit the pharmacologic action of the drugs. In our previous
study, incommodity was observed during drug administration.
BCP was usually dissolved in polyoxyethylated castor oil or olive
oil, hence, inaccurate dosages and several inconveniences in the
experimental operation are often encountered (Lou et al., 2016).
In the present study, the HPβCD/BCP was confirmed to be
effective and convenient. Thus, HPβCD/BCP was administrated
in rats with cognitive deficits for 4 weeks. The MWM test
and CBF monitoring results indicated that the HPβCD/BCP
treatment improved the learning and memory of the rats and
accelerated the recovery of their CBFs. These results suggested
that HPβCD/BCP elicits a cerebral protective effect in a dose-
dependent manner. Furthermore, no lesion was observed in the
brains of the rats in the sham group, indicating that HPβCD
exerted no effect on the BCP functions. Therefore, BCP played
a neuroprotective role by improving the blood supply in the
brain.
BCP was reported to be a CB2 selective agonist (Gertsch
et al., 2008; Al Mansouri et al., 2014; Bahi et al., 2014),
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FIGURE 10 | HE staining showed the effects of HPβCD/BCP on morphologic changes in hippocampal neurons caused by 2VO: sham group (A), 2VO
group (B), HPβCD/BCP low dose group (C), HPβCD/BCP middle dose group (D), HPβCD/BCP high dose group (E), and AM630 group (F). In the 2VO group,
neurons were paramorphia, their nuclei became triquetrous or polygonous, and the nerve fibers were fractured and reduced. In the HPβCD/BCP group, less abnormal
neurons were observed. In the AM630 group, the neurons were triquetrous and wedge-shaped, the nuclei were irregular, the cytoplasm was aggregated and the
nerve fibers were fractured and reduced. The red arrows showed the nerve fibers and the black arrows showed the abnormal neurons. The bar is 100 µm.
thus, it might elicit its neuroprotective effects by activating
the CB2. The CB2, which was used to be known as the
peripheral cannabinoid receptor type, was initially found in the
immune system, but was recently detected in the central nervous
system (Morgan et al., 2009; Lozovaya et al., 2011; Onaivi,
2011). In the present study, the immunohistochemistry results
showed that CB2 were expressed in brain tissues, especially
in neurons and nerve fibers. Moreover, the expression of
CB2 can be increased by BCP in a dose-dependent manner.
Administration of CB2 agonist can reduce the infract size of the
brain and motor functional deficits and restrain the production
of adhesion factor and matrix metalloproteinases, inhibit the
inflammatory response, and improve the microcirculation after
cerebral ischemia (Fernández-Ruiz et al., 2007; Benito et al., 2008;
Pini et al., 2012). The CB2 can be upregulated in multiple central
nervous system diseases, such as Alzheimer’s disease, Parkinson’s
disease, Huntington’s disease, and stroke (Capettini et al., 2012;
Javed et al., 2016). The CB2 signaling mechanism is associated
with the activation of the phosphatidylinositol 3-kinase (PI3K–
Akt) pathway (Molina-Holgado et al., 2002; Palazuelos et al.,
2006; Fernández-Ruiz et al., 2007). The PI3K/Akt pathway
exhibits neuroprotection against brain disorders (Enriquez-
Barreto et al., 2014; Gross and Bassell, 2014) and is associated
with learning and memory abilities.
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FIGURE 11 | TUNEL staining showed the effects of HPβCD/BCP on apoptosis in hippocampal neurons caused by 2VO: sham group (A), 2VO group (B),
HPβCD/BCP low dose group (C), HPβCD/BCP middle dose group (D), HPβCD/BCP high dose group (E), and AM630 group (F). The TUNEL positive cells in the 2VO
group significantly increased in the CA1 region of hippocampus compared with the sham group. After HPβCD/BCP treatment, the number of TUNEL positive cells
was obviously suppressed. And AM630 aggravated apoptosis in the hippocampus compared with the 2VO rats. The bar is 100 µm (*P < 0.001 vs. sham group,
##P < 0.001 vs. 2VO group).
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FIGURE 12 | Immunohistochemical staining showed the expressions of CB2 in corona radiata (a), pyramidal tract (b) and hippocampus CA1 region (c)
in different groups: sham group (A), 2VO group (B), BCP low dose group (C), BCP middle dose group (D), BCP high dose group (E), and AM630 group (F). The
expression levels of the CB2 increased in the 2VO group compared with those in sham group. The HPβCD/BCP significantly increased the expression levels of CB2,
and the CB2 expression levels increased with the increase of BCP concentration. In the AM630 group, the CB2 presented extremely low expression levels. The bar is
100 µm (*P < 0.01 vs. sham group, #P < 0.001 vs. 2VO group).
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FIGURE 13 | The expressions of CB2, PI3K and Akt in rats’ brain tissues of different groups. The expression levels of the CB2 and PI3K increased slightly in
the 2VO group compared with those in the sham group. After HPβCD/BCP treatment, the expression levels of CB2 and P13K, p-Akt increased compared with those
of the 2VO group, whereas these levels decreased in the AM630 treated group. (*P < 0.05 vs. sham group, #P < 0.05 vs. 2VO group, ##P < 0.01 vs. 2VO group).
In the present study, the CB2 was observed to be mainly
expressed in the cytoplasms of neurons and nerve fibers.
After 2VO operation, expression of CB2 slightly increased
possibly because of the compensatory protection mechanism.
BCP treatment can upregulate the expression of CB2 by
activating the PI3K/Akt pathway. However, AM630, a selective
CB2 antagonist, downregulated the expression of the CB2 and
suppressed the PI3K/Akt pathway, thus aggravating the ischemic
injury.
In conclusion, we prepared a novel drug delivery system for
BCP-HPβCD/BCP to improve its bioavailability. Administration
of the HPβCD/BCP alleviated the cognitive dysfunction,
improved the cerebral blood supply, suppressed neuronal
apoptosis, and reduced the loss of nerve fibers in VD model
rats. BCP possibly elicits its neuroprotective effects by activating
the CB2 pathway. Therefore, the present results may be of
considerable significance for targeted therapy and provide an
innovative treatment strategy for vascular dementia. Further
studies are required to determine the safety and possible side
effects of HPβCD/BCP and explore the detailed mechanism of
BCP on cognitive impairment.
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